23andMe_Logo_grey.png
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
September 12, 2024 16:05 ET | 23andMe, Inc.
SUNNYVALE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, in collaboration with lead researchers at...
Noom GLP-1
Noom Introduces Industry-First $149 Compounded GLP-1 with a Taper-Off Guarantee, Offering a Sustainable Approach to Long-Term Weight Loss
September 12, 2024 08:03 ET | Noom Inc
Noom will offer compounded GLP-1 injections paired with Noom’s powerful GLP-1 companion program, providing a sustainable pathway off the medications.
C3#3
KFSHRC Leads in Infectious Disease Diagnostics with Advanced Genomic Technologies
September 12, 2024 04:21 ET | King Faisal Specialist Hospital & Research Centre
KFSHRC Leads in Infectious Disease Diagnostics with Advanced Genomic Technologies
Le PIONeeR Project p
Le PIONeeR Project présentera pour la première fois les résultats de son étude clinique de phase Ib/IIa lors de l’ESMO 2024
September 12, 2024 04:21 ET | The PIONeeR Project
Le PIONeeR Project présentera pour la première fois les résultats de son étude clinique de phase Ib/IIa lors de l’ESMO 2024 Le symposium présidentiel "Eyes to the future" sera l'occasion de présenter...
logoPioneer plein.png
The PIONeeR Project to Present Late-Breaking Results from its Phase Ib/IIa umbrella study at the ESMO Congress 2024
September 12, 2024 04:21 ET | The PIONeeR Project
The PIONeeR Project to Present Late-Breaking Results from its Phase Ib/IIa umbrella study at the ESMO Congress 2024 The Presidential Symposium "Eyes to the future" will feature the first-ever...
C3#2
KFSHRC Announced a Strategic Partner for 2024 NYC C3 Summit Davos of Healthcare
September 11, 2024 10:16 ET | King Faisal Specialist Hospital & Research Centre
KFSHRC Announced a Strategic Partner for 2024 NYC C3 Summit Davos of Healthcare
sphericalinsightsoptionblue.png
Global Hematologic Malignancies Market Size To Worth USD 144.58 Billion By 2033 | CAGR Of 7.97%
September 06, 2024 02:00 ET | SPHERICAL INSIGHTS LLP
New York, United States , Sept. 06, 2024 (GLOBE NEWSWIRE) -- The Global Hematologic Malignancies Market Size is to Grow from USD 67.18 Billion in 2023 to USD 144.58 Billion by 2033, at a Compound...
OLON GROUP
Olon Continues its Growth Path and Announces a New Acquisition
September 04, 2024 05:00 ET | Olon SpA
MILAN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The acquisition plan involves a complete operational integration of Huvepharma Italia Srl and a plan to revive the production potential of the Garessio...
23andMe_Logo_grey.png
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024
September 03, 2024 07:30 ET | 23andMe, Inc.
Preliminary data from renal cancer and TMB-H/MSI-H cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented Analysis of CD200 as an exploratory tissue-based biomarker associated with...
LEB_4072
KFSHRC Concludes Participation at AMEE 2024 in Switzerland
August 29, 2024 02:56 ET | King Faisal Specialist Hospital & Research Centre
KFSHRC Concludes Participation at AMEE 2024 in Switzerland